Richard A. Miller, M.D.
Co-Founder, President and CEO
Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.
Joseph J. Buggy, Ph.D.
CO-FOUNDER AND EXECUTIVE VICE PRESIDENT, DISCOVERY RESEARCH
Dr. Buggy was with Pharmacyclics from 2006 to August 2013, where he was Vice President, Research from 2007 to August 2013, and served as project leader of the BTK inhibitor ibrutinib program. From 2001 to 2006, he was with Celera Genomics, where he served as Director in the Department of Biology, and, prior to that, Principal Scientist. Dr. Buggy earned a B.S. in microbiology from the University of Pittsburgh and a Ph.D. in molecular, cellular and development biology from Indiana University.
CHIEF FINANCIAL OFFICER
Mr. Lea served as the Chief Financial Officer of Pharmacyclics from 1998 to 2008. He received a B.S. in agricultural economics from the University of California, Davis, and an M.B.A. from the Anderson School at the University of California, Los Angeles.
Daniel W. Hunt, J.D.
SENIOR VICE PRESIDENT AND CHIEF BUSINESS OFFICER
Mr. Hunt served as General Counsel and Vice President of Corporate Development at CoMentis, a biotech company, from 2009 to 2016. Mr. Hunt also served as CEO of TelomeHealth and Vice President of Business Development at Zosanopharma. Mr. Hunt was an Associate General Counsel at Genentech. Prior to that, he held senior legal and transactional positions at Abgenix, Roche and Chiron. Mr. Hunt received a B.S in biology from the University of Colorado at Boulder and a J.D. from the Boalt Hall School of Law at the University of California, Berkeley.
James W. Janc, Ph.D.
VICE PRESIDENT, PHARMACOLOGY
Dr. Janc was with Theravance from 2006 to 2015, most recently as Senior Director of Research Technology. From 2000 to 2006, he was with Celera Genomics, most recently as Senior Director of Enzymology. Dr. Janc earned a B.A. in biochemistry from the University of Maryland and a Ph.D. in biochemistry from the University of Wisconsin-Madison. He was a National Institutes of Health (NIH) Postdoctoral Fellow in the Department of Chemistry at Johns Hopkins University.
William Ben Jones, Ph.D.
SENIOR VICE PRESIDENT, PHARMACEUTICAL DEVELOPMENT
Dr. Jones was Director of Global Regulatory Affairs in Sanofi U.S.’s oncology business unit from December 2012 to December 2014. From 2008 to March 2012, he was Director of Project Management & Regulatory at Pharmacyclics, where he played a principal role in the development of ibrutinib. Prior to Pharmacyclics, he was Associate Director of Development at Plexxikon and Senior Project Manager at Vertex Pharmaceuticals. Dr. Jones earned a B.S. and a Ph.D. in chemistry from the University of Cincinnati and completed a post-doctoral fellowship at the University of Oxford.
Long Kwei, Ph.D.
VICE PRESIDENT, BIOMETRICS & CLINICAL OPERATIONS
Dr. Kwei was Executive Director of Biostatistics at Pharmacyclics from November 2013 to July 2017. Prior to that, he served as the Site Head of Biometrics at AbbVie, Abbott Labs and PDL Biopharma before Abbott acquired the company. Prior to PDL Biopharma, he was the Executive Director of Biometrics at Tularik, then Amgen after Amgen’s acquisition of the company. From 1996 to 2001, he was with Roche, where he was the Site Head of Biometrics. Dr. Kwei earned a Ph.D. in biostatistics from the University of California, Berkeley.
Mehrdad Mobasher, M.D., MPH
VICE PRESIDENT AND CHIEF MEDICAL OFFICER
Dr. Mobasher joined Corvus in January 2019 from Genentech/ Roche where he worked from 2010 to 2018, most recently as a Group Medical Director and Development Lead for venetoclax. Dr. Mobasher steered the clinical development efforts for venetoclax through four successful Breakthrough Therapy designations from the FDA and three approvals granted under FDA’s priority review, two of which were under accelerated approval. He also was an adjunct clinical faculty member in the Division of Medical Oncology at Stanford University. Dr. Mobasher is the author of numerous papers published in peer-reviewed medical journals and multiple abstracts presented at medical conferences. Dr. Mobasher received an M.D. from Tehran University of Medical Sciences, and an M.P.H. in general epidemiology from the School of Public Health at the University of Michigan. He completed an internship and residency in internal medicine at the University of California, Irvine, and post-doctoral fellowships in hematology and medical oncology at Stanford University.
Erik Verner, Ph.D.
VICE PRESIDENT OF CHEMISTRY RESEARCH
Dr. Verner served as Director of Chemistry at Principia Biopharma from March 2011 to December 2014. Prior to that, he was with Pharmacyclics, where he served as Director of Chemistry from 2008 to February 2011 and principal scientist from 2006 to 2008. At Pharmacyclics, Dr. Verner was a co-inventor of ibrutinib and served as the lead chemist on the program. From 1996 to 2006, he served as a principal scientist at Axys Pharmaceuticals (formerly Arris Pharmaceuticals) and Celera Corporation, a subsidiary of Axys Pharmaceuticals. Dr. Verner earned a B.S. in chemistry from the University of Idaho and a Ph.D. in organic chemistry from the University of Pittsburgh.
Board of Directors
Ian T. Clark
Mr. Clark joined Genentech, Inc. in 2003 as Senior Vice President and General Manager, BioOncology. He subsequently held a number of senior management positions and was appointed CEO in January 2010, where he served until his retirement in December 2016. During his tenure, he led the Genentech Executive Committee and was a member of the Genentech Board of Directors. Prior to joining Genentech, Mr. Clark served as General Manager of Novartis Canada and, before that, as chief operating officer for Novartis United Kingdom. Earlier in his career, Mr. Clark served as vice president of sales and marketing for Sanofi (Aventis) and for Ivax in the United Kingdom, France and Eastern Europe. Mr. Clark also serves on the boards of Agios Pharmaceuticals, a public biotechnology company, Shire plc, a public biotechnology company, and Kite Pharmaceuticals, a public biotechnology company. Mr. Clark also serves on the boards of the Biotechnology Industry Organization (BIO) and the Gladstone Foundation, an independent, nonprofit life science research organization. He also serves as an advisor to the Institute of Life Sciences at Southampton University in the United Kingdom, as a member of the Federal Reserve Bank of San Francisco’s Economic Advisory Council, and as a member of the Technology Network Executive Council. Mr. Clark received a B.S. and an honorary doctorate in biological sciences from Southampton University.
Linda S. Grais, M.D., J.D.
Dr. Grais was president and chief executive officer of Ocera Therapeutics, Inc., a biopharma company developing new treatments for serious liver disease, until its acquisition by Mallinckrodt. Prior to that, she was a partner at InterWest Partners, a venture capital firm focused on biotechnology and medical device companies. Previously, Dr. Grais was a founder and executive vice president of Structural GenomiX, Inc., a drug discovery company focusing on new treatments for cancer that was acquired by Eli Lilly & Co. Earlier in her career, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she represented life science companies in venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant professor in the Department of Internal Medicine at the University of California, San Francisco. Dr. Grais currently serves on the board of directors of PRA Health Sciences, a large contract research organization, and serves on its Audit Committee. She also is on the board of directors of ARCA biopharma and Zosano Pharma. Dr. Grais received a B.A. in philosophy from Yale University, an M.D. from Yale Medical School, and a J.D. from Stanford Law School.
Elisha P. (Terry) Gould
Mr. Gould is a Partner and Head of Venture/Growth Equity Investments with Adam Street Partners. He invests in venture and growth-oriented companies with a focus on the healthcare space. Mr. Gould also sits on the board of directors of OncoMed Pharmaceuticals, Inc., LifeBond, Ltd. and Orbus Therapeutics, Inc. He is a former board member at Naurex, Inc. (acquired by Allergan plc), INC Research, Inc., Incline Therapeutics, Inc. (acquired by the Medicines Company) and Proteus Biomedical, Inc. Mr. Gould is also a member of the Adams Street Executive and Direct Investment Committees.
Steve E. Krognes
Mr. Krognes is Chief Financial Officer of Denali Therapeutics Inc., a biotechnology company. He served as Senior Vice President and Chief Financial Officer at Genentech, Inc., and Head of Mergers & Acquisitions at Roche Holding AG. Mr. Krognes is also a member of the board of directors of Gritstone Oncology, a public biotechnology company, the California Academy of Sciences, a scientific and educational institution, and was previously a member of the board of directors and board executive committee of the California Life Sciences Association, an industry organization. Mr. Krognes received a B.S. in economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.
Richard A Miller, M.D.
Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.
Peter Moldt, Ph.D.
Dr. Moldt has been a partner at Novo Ventures (U.S.) since May 2012. From 2009 to May 2012, Dr. Moldt was a partner at Novo A/S. In 2004, he co-founded Curalogic A/S, a Danish pharmaceutical company, where he served as CEO until 2009 and took the company public on the Copenhagen Stock Exchange in 2006. From 2000 to 2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years at NeuroSearch A/S, where he was responsible for all aspects of preclinical and clinical drug development. Dr. Moldt earned a Ph.D. in pharmacy and medicinal chemistry from the Royal Danish School of Pharmacy and completed post-doctoral work in the Department of Organic Chemistry at Yale University.
Scott W. Morrison
Mr. Morrison was a Partner with Ernst & Young LLP from 1996 to December 2015, where he also served as U.S. Life Sciences Leader from 2002 through December 2015. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Since January 2016, Mr. Morrison has served on the board and chairs the audit committees of Global Blood Therapeutics (GBT) and Audentes Therapeutics. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where he has served on the audit committee since 2002. Mr. Morrison also serves on the board of directors of Symic Bio, Inc., and Ideaya Biosciences Inc., privately held biotechnology companies. Mr. Morrison previously served on the boards of directors of the Life Sciences Foundation, a biotechnology nonprofit organization, the Bay Area Biosciences Association, a 501(c)(3) organization, and the Emerging Companies Section of the Biotechnology Industry Organization (BIO), a trade organization.
Peter Thompson, M.D.
Dr. Thompson is currently a Private Equity Partner with OrbiMed Advisors and has over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals, co-founded Cleave BioSciences, and serves as a director on the boards of several public and private companies. He previously held executive positions at Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist.